MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Nicholas G. Nickols, Ramin Nazarian, Shuang G. Zhao, Victor Tan, Vladislav Uzunangelov, Zheng Xia, Robert Baertsch, Elad Neeman, Allen C. Gao, George V. Thomas, Lauren Howard, Amanda M. De Hoedt, Josh Stuart, Theodore Goldstein, Kim Chi, Martin E. Gleave, Julie N. Graff, Tomasz M. Beer, Justin M. Drake, Christopher P. EvansRahul Aggarwal, Adam Foye, Felix Y. Feng, Eric J. Small, William J. Aronson, Stephen J. Freedland, Owen N. Witte, Jiaoti Huang, Joshi J. Alumkal, Robert E. Reiter, Matthew B. Rettig

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint Dive into the research topics of 'MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences